|Bid||0.00 x 1100|
|Ask||0.00 x 3100|
|Day's range||5.90 - 6.91|
|52-week range||3.62 - 11.10|
|Beta (5Y monthly)||1.74|
|PE ratio (TTM)||N/A|
|Earnings date||03 May 2021 - 07 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||7.13|
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, 2020, and provided an update on the Company’s clinical development programs and regulatory and commercial outlook for 2021.
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and year-end 2020 financial results on Tuesday, February 23, 2021, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the Company’s results in greater detail.
Clovis Oncology Presents Data in Advanced Prostate Cancer at ASCO GU 2021 Virtual Meeting